The advantages, pitfalls and limitations of guideline‐directed medical therapy in patients with valvular heart disease

Heart failure is an inevitable end‐stage consequence of significant valvular heart disease (VHD) that is left untreated and increasingly encountered in an ageing society. Recent advances in transcatheter procedures and improved outcomes after valve surgery mean that intervention can (and should) be considered in all patients – even the elderly and those with multiple comorbidities ‐ at earlier stages of the natural history of primary VHD, before the onset of irreversible left ventricular dysfunction (and frequently before the onset of symptoms). All patients with known VHD should be monitored carefully in the setting of a heart valve clinic and those who meet guideline criteria for surgical or transcatheter intervention referred for intervention without delay.

[1]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[2]  Y. Bossé,et al.  Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis , 2020, JACC. Basic to translational science.

[3]  John E A Blair,et al.  Impact of Loop Diuretic Use on Outcomes Following Transcatheter Aortic Valve Implantation. , 2020, The American journal of cardiology.

[4]  R. Guddeti,et al.  Lipoprotein(a) and calcific aortic valve stenosis: A systematic review. , 2020, Progress in cardiovascular diseases.

[5]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[6]  G. Mancia,et al.  Hypertension in aortic stenosis: a focused review and recommendations for clinical practice. , 2020, Journal of hypertension.

[7]  Kiyoshi Yoshida,et al.  Subtypes of Atrial Functional Mitral Regurgitation: Imaging Insights Into Their Mechanisms and Therapeutic Implications. , 2020, JACC. Cardiovascular imaging.

[8]  B. Prendergast,et al.  Secondary mitral regurgitation: pathophysiology, proportionality and prognosis , 2020, Heart.

[9]  J. Chambers Specialist valve clinic: why, who and how? , 2019, Heart.

[10]  S. Stewart,et al.  Poor Long-term Survival in Patients with Moderate Aortic Stenosis. , 2019, Journal of the American College of Cardiology.

[11]  G. Keren,et al.  Tricuspid regurgitation and long-term clinical outcomes. , 2019, European heart journal cardiovascular Imaging.

[12]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[13]  Wei-Chieh Lee,et al.  Ivabradine for the Treatment of Acute Mitral-Regurgitation-Related Decompensated Heart Failure , 2019, Cardiology.

[14]  S. Kapadia,et al.  Outcomes of patients with severe tricuspid regurgitation and congestive heart failure , 2019, Heart.

[15]  M. Packer,et al.  Neurohormonal and Transcatheter Repair Strategies for Proportionate and Disproportionate Functional Mitral Regurgitation in Heart Failure. , 2019, JACC. Heart failure.

[16]  Jeroen J. Bax,et al.  Aortic Stenosis and Heart Failure: Disease Ascertainment and Statistical Considerations for Clinical Trials , 2019, Cardiac failure review.

[17]  S. Yun,et al.  Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study , 2019, Circulation.

[18]  M. Enriquez-Sarano,et al.  Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. , 2019, JACC. Cardiovascular imaging.

[19]  S. Kaveh,et al.  Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis , 2019, International Journal of Clinical Pharmacy.

[20]  C. Yancy,et al.  Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges , 2018, European journal of heart failure.

[21]  D. Maucort-Boulch,et al.  Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.

[22]  B. Prendergast Faculty of 1000 evaluation for 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2018 .

[23]  P. Pellikka,et al.  Reduced Left Ventricular Ejection Fraction in Patients With Aortic Stenosis. , 2018, Journal of the American College of Cardiology.

[24]  W. Aronow Hypertension, aortic stenosis, and aortic regurgitation. , 2018, Annals of translational medicine.

[25]  P. Okin,et al.  Antihypertensive Treatment With β‐Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events , 2017, Journal of the American Heart Association.

[26]  A. Sannino,et al.  Survival and Cardiovascular Outcomes of Patients With Secondary Mitral Regurgitation: A Systematic Review and Meta-analysis , 2017, JAMA cardiology.

[27]  J. Sörensen,et al.  Metoprolol Reduces Hemodynamic and Metabolic Overload in Asymptomatic Aortic Valve Stenosis Patients: A Randomized Trial , 2017, Circulation. Cardiovascular imaging.

[28]  M. Claeys,et al.  Evolution of Functional Mitral Regurgitation and Prognosis in Medically Managed Heart Failure Patients With Reduced Ejection Fraction. , 2017, JACC. Heart failure.

[29]  J. Mascherbauer,et al.  Refining the prognostic impact of functional mitral regurgitation in chronic heart failure , 2017, European heart journal.

[30]  P. Ponikowski,et al.  Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.

[31]  E. Frangou,et al.  Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. , 2016, European heart journal.

[32]  M. Leon,et al.  Medical Treatment of Aortic Stenosis , 2016, Circulation.

[33]  D. Mele,et al.  Role of cardiac dyssynchrony and resynchronization therapy in functional mitral regurgitation. , 2016, European heart journal cardiovascular Imaging.

[34]  R. Nicoll,et al.  The effect of statins on valve function and calcification in aortic stenosis: A meta-analysis. , 2016, Atherosclerosis.

[35]  S. Urheim,et al.  Controlled release metoprolol for aortic regurgitation: a randomised clinical trial , 2015, Heart.

[36]  J. Afilalo,et al.  Complications Associated With Nitrate Use in Patients Presenting With Acute Pulmonary Edema and Concomitant Moderate or Severe Aortic Stenosis. , 2015, Annals of emergency medicine.

[37]  I. Burwash,et al.  Low Gradient Aortic Stenosis , 2015, Current Treatment Options in Cardiovascular Medicine.

[38]  B. Prendergast,et al.  A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) , 2015, European heart journal cardiovascular Imaging.

[39]  K. Alexander,et al.  Futility, benefit, and transcatheter aortic valve replacement. , 2014, JACC. Cardiovascular interventions.

[40]  K. Swedberg,et al.  Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). , 2014, The American journal of cardiology.

[41]  A. Bogers,et al.  Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. , 2013, Journal of the American College of Cardiology.

[42]  S. Saba,et al.  Mechanistic Features Associated With Improvement in Mitral Regurgitation After Cardiac Resynchronization Therapy and Their Relation to Long-Term Patient Outcome , 2013, Circulation. Heart failure.

[43]  M. Dweck,et al.  Calcific aortic stenosis: a disease of the valve and the myocardium. , 2012, Journal of the American College of Cardiology.

[44]  Benjamin R. Szwejkowski,et al.  The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. , 2011, Journal of the American College of Cardiology.

[45]  M. Keane,et al.  Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. , 2011, Journal of the American College of Cardiology.

[46]  K. Swedberg,et al.  Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy , 2011, European heart journal.

[47]  M. Enriquez-Sarano,et al.  Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2011, Heart.

[48]  J. Junttila,et al.  Respective Prevalence of the Different Carpentier Classes of Mitral Regurgitation: A Stepping Stone for Future Therapeutic Research and Development , 2011, Journal of cardiac surgery.

[49]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[50]  P. Varadarajan,et al.  Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients. , 2009, Journal of the American College of Cardiology.

[51]  W. Gaasch,et al.  Left ventricular response to mitral regurgitation: implications for management. , 2008, Circulation.

[52]  M. Gold,et al.  REsynchronization reVErses Remodeling in Systolic left ventricular dysfunction (REVERSE) , 2008 .

[53]  H. White,et al.  A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. , 2008, American heart journal.

[54]  H. Tsutsui [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[55]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[56]  C. Pappone,et al.  Role of regional mechanical dyssynchrony as a determinant of functional mitral regurgitation in patients with left ventricular systolic dysfunction , 2006, Heart.

[57]  A. Evangelista,et al.  Long-term vasodilator therapy in patients with severe aortic regurgitation. , 2005, The New England journal of medicine.

[58]  M. Enriquez-Sarano,et al.  Heart Failure and Death After Myocardial Infarction in the Community: The Emerging Role of Mitral Regurgitation , 2005, Circulation.

[59]  S. Solomon,et al.  Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.

[60]  R Alagesan,et al.  Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). , 2004, American heart journal.

[61]  M. Böhm,et al.  Increased exercise ejection fraction and reversed remodeling after long‐term treatment with metoprolol in congestive heart failure: a randomized, stratified, double‐blind, placebo‐controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy , 2003, European journal of heart failure.

[62]  E. Tuzcu,et al.  Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. , 2003, The New England journal of medicine.

[63]  D. Delurgio,et al.  Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.

[64]  J. Gómez-Hospital,et al.  Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction. , 2002, Transplantation proceedings.

[65]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[66]  F. Ståhlberg,et al.  Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation. , 2000, American heart journal.

[67]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[68]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[69]  W. Abraham,et al.  Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. , 1999, The American journal of cardiology.

[70]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[71]  T. Levine,et al.  Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. , 1998, The American journal of cardiology.

[72]  W. Rydlewska-sadowska,et al.  Captopril or nifedipine? Comparison of rest and exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe aortic regurgitation. , 1998, The Journal of heart valve disease.

[73]  W. Gaasch,et al.  Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. , 1996, Journal of the American College of Cardiology.

[74]  S. Rahimtoola,et al.  Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. , 1994, The New England journal of medicine.

[75]  H. Schön Hemodynamic and morphologic changes after long‐term angiotensin converting enzyme inhibition in patients with chronic valvular regurgitation , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[76]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[77]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[78]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[79]  J. Spann,et al.  Differences in myocardial performance and load between patients with similar amounts of chronic aortic versus chronic mitral regurgitation. , 1984, Journal of the American College of Cardiology.

[80]  B MAYNE,et al.  On aortic regurgitation , 1953, Irish journal of medical science.

[81]  G. Mancia,et al.  Antihypertensive treatment with calcium channel blockers in patients with moderate or severe aortic stenosis: Relationship with all-cause mortality. , 2019, International journal of cardiology.

[82]  P. Voisine,et al.  Transcatheter Mitral-Valve Repair in Patients with Heart Failure. , 2019, The New England journal of medicine.

[83]  M. Cheitlin Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2012 .

[84]  M. Cheitlin Cardiac Resynchronization Induces Major Structural and Functional Reverse Remodeling in Patients With New York Heart Association Class I/II Heart Failure , 2011 .

[85]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.